Join our daily newsletter At The Bell to receive exclusive market insights
- MedAdvisor (MDR) has extended its health program deal with U.S. pharmaceutical company Adheris for another three months
- A US$3.4 million (roughly A$4.4 million) deal was inked in December last year and had a five-month term
- Pleasingly, the extension is for a shorter term but has a greater value of US$4.7 million (roughly A$6.19 million)
- The health programs deliver personalised content to the right patients to make them aware of the benefits of certain medication vaccines
- MedAdvisor ended the day up 6.15 per cent with shares closing at 34.5 cents
MedAdvisor (MDR) has reported U.S. pharmaceutical company Adheris has extended its health program deal for about three months.
This deal is an extension to the five-month agreement announced in December last year.
The original deal was valued at US$3.4 million (roughly A$4.4 million), whereas the extension deal has an estimated value of US$4.7 million (roughly A$6.19 million).
“We’re delighted to have another health program extended in the U.S. market,” MedAdvisor CEO and Managing Director Robert Read said.
“These health programs deliver tailored content specifically to the right patients based on advanced algorithms and are designed to ensure they are aware of the benefits of certain medications vaccines,” he added.
MedAdvisor’s technology platform allows user to connect to their local pharmacy and automatically keep up to date with prescriptions, medication doses, and doctors appointments.
Under the deal, Adheris is offering its network of 25,000 pharmacies with an opt-out population of about 180 million patients to deliver direct mail to patients at the right time. According to the company, The deal complements MedAdvisor’s existing offering, which ensures patients stay on top of their health.
MedAdvisor ended the day up 6.15 per cent with shares closing at 34.5 cents.
